An observational study in Diabetes, Obesity and PreDiabetes, sponsored by Medical University of Bialystok. Recruiting at 1 site in Poland. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Medical University of Bialystok · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Prediabetic State with a site in Poland — 6 open to participants now, 6 under way, none of them phase 3. Prediabetic State · Poland.
Among the 11 studies in Prediabetic State with a site in Poland, this one is one of 2 that started in 2020, is one of 2 observational ones, and was the 7th registered.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
Browse Prediabetic State studies →6 of the 11 studies in Prediabetic State with a site in Poland are open now. Recruiting first, the newest first:
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18–80
PolTREG S.A. · Sites in Poland
Ages 3–18
AronPharma Sp. z o. o. · Sites in Poland
Ages 18–75
Medical University of Bialystok · Sites in Poland
Ages 18–65 · Healthy volunteers
Medical University of Bialystok · Sites in Poland
Ages 18+ · Healthy volunteers
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 224 across 129 observational studies indexed under Prediabetic State.
Median enrollment 300 across the 9 interventional studies, 5,500 across the 2 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 8 most frequent:
Medical University of Bialystok is the lead sponsor of 72 studies on the registry; 18 are open to participants now.
Medical University of Bialystok has 4 studies filed under Prediabetic State — fewer than ten, so there is no comparison to draw.
1 of the studies in Prediabetic State with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04634591Medical University of BialystokThe Bialystok Bariatric Surgery Study | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Prediabetic State with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this project is to create a registry of diabetic patients, containing a detailed clinical profile of each patient, along with omics data, which will be analyzed using artificial intelligence algorithms, and their results will be implemented in the form of new recommendations of care for high-risk patients and those already suffering from diabetes.
The study will be conducted prospectively. The project participants will be patients with diabetes, patients at high risk of developing diabetes and a control group of normoglycemic patients who will participate in study visits at the Clinical Research Center of the Medical University of Bialystok.
The aim of this project is to create a registry of patients at risk of developing diabetes or already diagnosed with diabetes, containing a detailed clinical profile of each patient, along with omics data, which will be analyzed using artificial intelligence algorithms, and their results will be implemented in the form of new recommendations of care for high-risk patients and those already suffering from diabetes.
The study will be conducted prospectively. The project participants will be patients with diabetes, patients at high risk of developing diabetes and a control group of normoglycemic patients who will participate in study visits at the Clinical Research Center of the Medical University of Bialystok.
As part of the project, each patient will participate in one visit at the research center. During the visit, each patient will undergo a detailed medical interview regarding the current health condition, the course of previously diagnosed diseases, family history, physical activity and diet. In addition, venous blood will be taken for each patient, from which the basic metabolic parameters will be determined (including glucose, lipid profile, HbA1c, AST, ALT, GGTP, electrolytes, blood count with smear, presence of antibodies against beta-cell antigens, TSH, ACTH) and omics analyzes will be performed (including genotyping and sequencing of DNA, transcriptomics, metabolomics, proteomics and lipidomics). Additionally, from each patient, saliva, urine, stool sample, and skin and nasal swabs to assess the microbiome will be collected. Each patient will also receive a detailed body composition analysis using bioimpedance and densitometry (DXA) and grip strength analysis. Non-diabetic patients will also undergo an oral glucose load test (OGTT).
In addition, patients who give additional consent will be able to participate in additional visits, including abdominal MR imaging with the assessment of liver steatosis, a biopsy of the vastus lateralis muscle, cardio-pulmonary exercise test, metabolic clamp (euglycemic - hyperinsulinemic) and glycemia assessment using the continuous glucose monitoring system ( CGM).
As part of the project, we plan for follow-up each participant with re-visits in the study centre every five years, covering exactly the same schedule of visits as the patient will make the first time.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 224 across 129 observational studies indexed under Prediabetic State.
Browse Prediabetic State studies →Medical University of Bialystok is the lead sponsor of 72 studies on the registry; 18 are open to participants now.
Compared within Prediabetic State, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The project participants will be patients with diabetes, patients at high risk of developing diabetes (prediabetes) and a control group of normoglycemic patients from Poland.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with diagnosed diabetes
Other: Observational study - registry
Patients with diagnosed prediabetes defined as impaired fasting glucose and/or impaired glucose tolerance
Other: Observational study - registry
Patients with normoglycemia, based on the OGTT - normal fasting glucose and normal glucose tolerance
Other: Observational study - registry
Observational study - registry
HbA1c
Haemoglobin A1c measured by the high-performance liquid chromatography (HPLC) method
Time frame: every 5 years
Fasting glucose
Fasting glucose concentration measured in plasma using the colorimetric method
Time frame: every 5 years
2-hour glucose
Glucose concentration at 2-hour of the oral glucose tolerance test, measured in plasma using the colorimetric method - only in non-diabetic subjects
Time frame: every 5 years
Fasting insulin
Fasting insulin concentration measured in plasma using the immunoradiometric assay (IRMA)
Time frame: every 5 years
Lean body mass
Total lean body mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)
Time frame: every 5 years
Fat mass
Total body fat mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)
Time frame: every 5 years
Visceral Adipose Tissue mass
Visceral adipose tissue mass measured using the whole-body dual-energy X-ray absorptiometry (DXA)
Time frame: every 5 years
Weight
Total body weight measured using standardized scale
Time frame: every 5 years
Homeostatic model assessment for insulin resistance (HOMA-IR)
Homeostatic model assessment for insulin resistance
Time frame: every 5 years
Homeostatic model assessment of beta cell function (HOMA-beta)
Homeostatic model assessment of beta cell function
Time frame: every 5 years
VO2max
Maximal oxygen consumption measured during cardio-pulmonary exercise test
Time frame: every 5 years
Triglycerides (TG)
Serum triglycerides concentration measured using colorimetric method
Time frame: every 5 years
High-density lipoprotein cholesterol (HDL)
Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric method Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric method Serum high-density lipoprotein cholesterol (HDL) concentration measured using colorimetric meth
Time frame: every 5 years
Low-density lipoprotein cholesterol (LDL)
Serum low-density lipoprotein cholesterol (LDL) concentration measured using colorimetric method
Time frame: every 5 years
Total cholesterol
Serum total cholesterol concentration measured using colorimetric method
Time frame: every 5 years
Plasma metabolome
plasma metabolites concentrations measured using untargeted metabolomics
Time frame: every 5 years
Skeletal muscle transcriptome
skeletal muscle gene and smallRNA expressions measured using untargeted transcriptomics
Time frame: every 5 years
Skeletal muscle metabolome
skeletal muscle metabolites concentrations measured using untargeted metabolomics
Time frame: every 5 years
Plasma microRNAs
Expression of circulating smallRNA
Time frame: every 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Dec 2030, 130 months after the start.
Of 48 observational studies under Prediabetic State, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 24. This study's planned 130 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Bialystok